US RE39050 Landscape: Claim Scope, Coverage, and Practical Patent Positioning

US patent RE39050 is a reissue of an earlier patent family for a method of inhibiting post-menopausal bone loss/bone resorption using a compound of Formula I (or a pharmaceutically acceptable salt/solvate), with dose-defined oral administration windows centered on ~60 mg/day, and claim sets that narrow further to a hydrochloride salt at 60 mg/day.

What does RE39050 actually claim? (Core claim structure)

Independent claim (claim 1): method + patient population + disease function + drug class + dose range

Claim 1 is the functional and dosing anchor:

Purpose/function: “inhibiting post-menopausal bone loss or bone resorption”
Indication timing: “to prevent or to treat post-menopausal osteoporosis”
Patient: “a post-menopausal woman in need of treatment”
Dosage form: “administering… a compound of formula I or a pharmaceutically acceptable salt or solvate thereof”
Dose range: “about 50 to about 150” and later in the same claim text also indicates “55 to 65 mg/day” (the claim set you provided includes both ranges as written)

In practical coverage terms, claim 1 is broad on:

indication framing (prevention and treatment),
drug selection (Formula I compound and acceptable salts/solvates),
and dose range (at least one broad bracket is present from the claim text you provided).

It is narrower on:

population (post-menopausal woman in need of treatment),
clinical target (bone loss/bone resorption in the post-menopause context),
administration amount (mg/day).

Claim 2–5: condition and demographic narrowing

Claim 2: patient diagnosed with post-menopausal osteoporosis.
Claim 3: human is a post-menopausal female.
Claim 4: human is a male.
Claim 5: administration prophylactically.

These dependents tighten clinical framing and patient subset. The notable scope lever is claim 4 allowing male subjects while remaining anchored to the claim 1 method structure (post-menopausal bone loss framing). That makes the dependents relevant for cross-gender off-label use only if the claim construction allows “post-menopausal” to be interpreted functionally or if the reissue paper provides context. Based on the text supplied, claim 4 exists as a written dependent.

Claim 6–11: explicit dosing buckets

These are dose-specific embodiments of the Formula I compound:

Claim 6: “about 60 to about 150 mg/day”
Claim 7: “60 mg/day”
Claim 8: includes “75 55 mg/day” as written (presented in your text as two numbers in one claim line)
Claim 9: “100 65 mg/day” as written
Claim 10: “125 mg/day”
Claim 11: “150 mg/day”

The commercial relevance is straightforward: if an accused product uses a dosing regimen falling in any of these numeric windows, it can land inside the dependent claim set even where claim 1 is contested (for example, if claim 1’s dose language is attacked for internal inconsistency between the “50 to 150” bracket and the “55 to 65” snippet in your text).

Claim 12–15: hydrochloride-salt embodiments at 60 mg/day

This is the clearest narrow coverage:

Claim 12: “administering a hydrochloride salt of a compound of formula I.”
Claim 13: hydrochloride salt at 60 mg/day
Claim 14: prevent post-menopausal osteoporosis using hydrochloride salt at 60 mg/day
Claim 15: treat post-menopausal osteoporosis using hydrochloride salt at 60 mg/day

Claims 12–15 convert the broad Formula I method into a specific salt + specific dose carve-out.

How broad is the coverage? (Claim-by-claim scope map)

1) Chemical scope

Formula-level coverage is Formula I plus salts/solvates (claim 1).
Narrowed chemical scope to hydrochloride salt (claims 12–15).

A competitor’s freedom depends on whether the product:

uses a compound that meets “Formula I” (structural equivalence via claim construction), and/or
uses the hydrochloride salt versus another salt form.

2) Indication scope

Claim 1 includes both prevention and treatment.
Claims 14 and 15 separate prevention and treatment at the 60 mg/day hydrochloride embodiment.

If the accused product is positioned strictly as “prevention” or “treatment,” it still sits within the same broad method framework of claim 1. The most litigation-sensitive difference is dose and salt, not the prevention/treatment framing, because claim 1 already captures both.

3) Population scope

Claim 1: post-menopausal woman.
Claim 4: male inclusion.
Claims 2–3: female subset and diagnosis specifics.

In practice, “male” dependent claim language is relevant for:

regulatory label expansion scenarios,
clinical trials that enroll men for bone resorption endpoints,
and off-label use arguments.

4) Dose scope

The dosing scaffolding is the strongest operational handle for assessing infringement risk. RE39050 presents multiple numeric ranges:

Broad: “about 50 to about 150” (as written) and also “55 to 65 mg/day” (as written in your excerpt).
Medium: “about 60 to about 150 mg/day” (claim 6).
Fixed points: 60 mg/day, 100 mg/day, 125 mg/day, 150 mg/day.
Hydrochloride-salt fixed point: 60 mg/day (claims 13–15).

A product’s dosing regimen can be compared directly to these buckets.

Where are the likely “hot spots” in the claim set?

Hot spot A: hydrochloride salt at 60 mg/day (claims 13–15)

This is the narrowest and likely most enforceable slice:

If an accused product uses a hydrochloride salt form and is dosed at 60 mg/day, it maps directly into claims 13–15 with minimal argument over dose.

Hot spot B: 60 mg/day and nearby windows (claims 6–11 + claim 1)

Even if the accused product uses a non-hydrochloride salt or different solvate:

claims 7 (60 mg/day),
claim 6 (60 to 150 mg/day “about” range),
and claim 1’s dose language (depending on claim construction of the conflicting snippets in your excerpt) create multiple infringement entry points.

Hot spot C: the method function (bone loss/bone resorption)

Infringement will turn on whether the product is administered for the claimed method purpose (prevent/treat osteoporosis; inhibit post-menopausal bone loss/bone resorption). If a label or physician protocol ties the regimen to these endpoints, it supports the method claim’s “in need of treatment to prevent or treat” phrasing.

Patent landscape positioning: what RE39050 implies about the broader family

A reissue patent that includes:

Formula-driven composition language (“compound of Formula I or pharmaceutically acceptable salt/solvate”),
method claims for osteoporosis endpoints,
and extensive dose-specific dependent claims (including a salt-specific 60 mg/day branch),

typically indicates the family landscape is structured around: 1) a core chemical scaffold (Formula I) protected in earlier filings, 2) pharmacological use around post-menopausal osteoporosis and bone resorption inhibition, 3) salt form and dose regimen variations that create additional claim islands for market entry.

Within that typical pattern, the reissue often appears where:

earlier claims required narrowing or correction,
or where dose/salt embodiments were added or clarified to improve enforceability against generic or reformulated entries.

Actionable infringement mapping framework (how to stress-test a competing product quickly)

Step 1: Dose match

Check whether the accused regimen falls within any of the following written claim dose constraints:

60 mg/day (claims 7, 13–15)
about 60 to about 150 mg/day (claim 6)
100 mg/day (claim 9 as written contains “100 65 mg/day”)
125 mg/day (claim 10)
150 mg/day (claim 11)
the dose language in claim 1 as provided (“about 50 to about 150” and the “55 to 65 mg/day” fragment)

If the regimen misses all fixed points but lands in “about” ranges, claim 1 and claim 6 become the main targets.

Step 2: Salt form match

If the accused product is the hydrochloride salt of Formula I, claims 12–15 are directly implicated.
If not hydrochloride, claims 1–11 still remain in play for the method using “acceptable salts/solvates.”

Step 3: Indication/purpose alignment

The label matters for method claims: “prevent or treat post-menopausal osteoporosis” and inhibition of “bone loss/bone resorption” aligns strongly.
Prophylactic framing can implicate claim 5, but claim 1 already includes prevention.

Step 4: Patient population

If trials or real-world use involve post-menopausal women, claim 1 is naturally implicated.
If male bone resorption endpoints are involved, claim 4 provides an additional hook on the face of the dependent text.

What does RE39050 leave competitors with? (Freedom-to-operate implications)

Given the claim structure you provided, potential design-arounds are constrained:

Switching away from hydrochloride may avoid claims 12–15, but not necessarily claims 1–11.
Switching dose is more consequential:
- stepping outside the fixed numeric claims and outside “about 60 to about 150” can reduce straightforward mapping,
- but claim 1’s dose language (as written in your excerpt) still creates risk if courts construe it broadly.
Changing the clinical purpose is difficult because claim 1 already covers “to prevent or to treat” and the functional endpoint is “inhibiting post-menopausal bone loss or bone resorption.”

The practical result is that the strongest non-infringing alternative typically requires both:

a salt form that is not hydrochloride, and
a dose regimen that is outside the specific windows and the broad method claim dose language.

Key tables

Table 1: Claim scope slices by structural and regulatory levers

Lever	Claims	Coverage implication
Formula I compound	Claim 1	Broad scaffold coverage using compound of Formula I (and salts/solvates)
Salt/solvate	Claim 1; Claims 12–15	Claim 1 covers acceptable salts/solvates; Claims 12–15 focus on hydrochloride
Indication	Claim 1; Claims 14–15	Prevention and treatment covered; salt-specific embodiments separate prevention vs treatment
Population	Claim 1; Claims 2–4	Post-menopausal woman in need; dependent adds male and diagnosis specifics
Dose (broad/fixed)	Claim 1; Claims 6–11	Multiple dose windows and fixed mg/day points create several infringement entry points
Hydrochloride + dose	Claims 12–15	Narrowest enforceable segment if an accused product uses hydrochloride at 60 mg/day

Table 2: Dose-specific dependent claims (as written in your excerpt)

Claim	Dose language in provided text
6	about 60 to about 150 mg/day
7	60 mg/day
8	“75 55 mg/day” (as written)
9	“100 65 mg/day” (as written)
10	125 mg/day
11	150 mg/day
13	hydrochloride salt at 60 mg/day
14	hydrochloride salt at 60 mg/day (prevention)
15	hydrochloride salt at 60 mg/day (treatment)

What to watch in litigation: claim construction pressure points

1) Dose language reconciliation in claim 1
Your excerpt shows multiple dose brackets inside claim 1 (a “50 to 150” style range and a “55 to 65 mg/day” snippet). In infringement, this becomes a claim construction and interpretation issue that can materially affect whether a dosing regimen fits claim 1 versus only the dependent dose claims.

2) “Hydrochloride salt” scope
If an accused product is a different salt or a hydrate/solvate that is not encompassed as “hydrochloride,” claims 12–15 become a focal line of defense.

3) “Post-menopausal” framing vs male dependent claim
Claim 4’s male inclusion could be attacked based on the ordinary meaning of “post-menopausal woman,” but because it is a dependent claim, its meaning will be tied to the dependency chain and the reissue’s internal claim context.

Key Takeaways

RE39050’s enforcement leverage is concentrated in method claims for inhibiting post-menopausal bone loss/bone resorption using Formula I (or salts/solvates), with dose-driven dependent claims.
The highest-risk slice for competitors is hydrochloride salt at 60 mg/day (claims 13–15).
Multiple dependent claims create several numerical infringement entry points at 60 mg/day, 100 mg/day, 125 mg/day, and 150 mg/day (as written), plus “about 60 to about 150 mg/day.”
Salt form and dose regimen are the primary practical levers; indication framing (prevention vs treatment) is not a strong escape route because claim 1 already covers both.

FAQs

1) Which claims are most directly implicated if a product is dosed at 60 mg/day?
Claims 7, 13, 14, and 15, plus claim 1 and claim 6 depending on dose construction.

2) How does switching from hydrochloride reduce risk?
It can avoid claims 12–15 specifically, but claims 1–11 still cover the method using “a compound of Formula I or pharmaceutically acceptable salt or solvate.”

3) Do the claims require diagnosis of post-menopausal osteoporosis?
Not for claim 1, but claim 2 does require diagnosis.

4) Are the claims limited to women?
Claim 1 is directed to a post-menopausal woman, while claim 4 adds a male-dependent embodiment.

5) What is the key quantitative barrier competitors must evaluate?
The regimen must be compared against the explicit dose claims (including 60 mg/day and “about 60 to about 150 mg/day”) and against the dose language in claim 1 as written.

References (APA)

[1] US patent RE39050, reissue patent publication record and claims (provided claim text).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	1355195	⤷ Start Trial
Australia	702575	⤷ Start Trial
Brazil	9500784	⤷ Start Trial
Canada	2141999	⤷ Start Trial
China	1119530	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: RE39050

Summary for Patent: RE39050